WITTE OWEN N. 4
4 · Allogene Therapeutics, Inc. · Filed Oct 17, 2018
Insider Transaction Report
Form 4
WITTE OWEN N.
Director
Transactions
- Conversion
Series A Convertible Preferred Stock
2018-10-15−7,130→ 0 total→ Common Stock (37,432 underlying) - Purchase
Common Stock
2018-10-15$18.00/sh+15,000$270,000→ 198,750 total - Conversion
Common Stock
2018-10-15+37,432→ 236,182 total
Footnotes (1)
- [F1]The Series A Convertible Preferred Stock converted on a 5.25-for-1 basis and had no expiration date.